Biopharma
Found 13 companies.
🏢 Roivant Sciences
👥 501-1000💰 $230,000,000 Post-IPO Equity almost 2 years ago🫂 Last layoff about 2 years agoPharmaceuticalBiotechnologyBiopharmaProduct ResearchHealth Care📈 Public Company
Website LinkedIn Email Facebook Twitter

Roivant Sciences is a biopharmaceutical company accelerating the development of promising late-stage drug candidates. We achieve this by building and supporting nimble, entrepreneurial biotech companies (Vants), leveraging a unique approach to talent acquisition, incentive alignment, and technology deployment. Our focus is on reducing the time and cost of bringing new medicines to market, ultimately improving patient lives and benefiting the healthcare system. We've successfully launched VTAMA®, achieved multiple FDA approvals, and secured significant global partnerships. This rapid growth has been fueled by strategic in-licensing, acquisitions, and a commitment to innovation. Our tech-enabled approach is central to our success. We utilize a robust technology stack including iPhone/Mobile compatibility, Google Tag Manager, Google Analytics, and a Content Delivery Network (CDN), ensuring efficient data management and streamlined operations. We foster a dynamic, collaborative environment, embracing both remote and in-person work models. Our engineering culture values agility, innovation, and a data-driven approach to problem-solving. Roivant's mission is to dramatically improve healthcare outcomes. We are a large company, currently employing between 501 and 1000 people, and we strive to create a rewarding and impactful workplace. We value both individual achievement and collaborative teamwork. We offer a range of exciting opportunities across multiple therapeutic areas, in both clinical development and tech-focused operations. Our significant funding and consistent success position us for continued growth and leadership in the biopharmaceutical industry. Roivant prioritizes diversity, equity, and inclusion. We are proud of our diverse workforce and offer a supportive and inclusive environment where every employee's contributions are valued. We embrace remote work, offering flexibility and empowering employees to perform at their best, regardless of location. With offices globally, we're a dynamic organization continually seeking talented and passionate individuals to join our mission.

🏢 Datavant
👥 1001-5000💰 $40,000,000 Series B over 4 years agoBiopharmaClinical TrialsData IntegrationHealth CareSoftware💼 Private Company
Website LinkedIn Email Twitter

Datavant is a healthcare data logistics company that connects and moves data securely for organizations, providing solutions for data integration and collaboration.

🏢 Bruker BioSpin
👥 5001-10000PharmaceuticalBiotechnologyBiopharma
Website LinkedIn Facebook Twitter

Bruker BioSpin is a leading provider of scientific instruments and analytical solutions for life science research and industry applications, employing over 5,000 people.

🏢 Cytokinetics
👥 251-500💰 $550,000,000 Post-IPO Equity 8 months agoBiotechnologyBiopharmaHealth Care📈 Public Company
Website LinkedIn Email Facebook Twitter

Cytokinetics is a late-stage biopharmaceutical company pioneering the development of first-in-class muscle activators and next-in-class muscle inhibitors. We focus on treating debilitating diseases where muscle performance is compromised, primarily within the cardiovascular therapeutic area. Our innovative approach to muscle biology and the mechanics of muscle performance is driving the development of small molecule drug candidates to improve myocardial muscle function and contractility. Aficamten, our leading drug candidate, is currently making a significant impact in the treatment of hypertrophic cardiomyopathy. Our team utilizes a robust technology stack that includes WordPress, Amazon web services for hosting, and various tools like Google Tag Manager for analytics and Font Awesome for design. We value collaboration and a data-driven approach, ensuring our engineering practices are efficient and effective. Our mission is to improve patients' lives, which is reflected in our commitment to rigorous scientific thinking, integrity, and ethical practices. We're a values-driven company that encourages teamwork, innovation and puts patients at the heart of everything we do. Cytokinetics is a publicly traded company (NASDAQ: CYTK) with 251-500 employees. We boast a strong funding history and are actively expanding our global reach, with opportunities for both in-office and remote work across multiple departments and functions. We encourage individuals passionate about making a difference in the lives of patients with cardiovascular diseases to explore our career opportunities. We champion diversity and inclusion and are an equal opportunity employer.

🏢 MapLight Therapeutics
👥 11-50💰 $225,000,000 Series C about 1 year agoBiotechnologyBiopharmaMedicalLife Science💼 Private Company
Website LinkedIn Email Twitter

MapLight Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of innovative therapies for central nervous system disorders. We leverage a unique platform combining single-cell transcriptomics and optogenetics to identify novel drug targets and create effective treatments for debilitating brain conditions such as schizophrenia and Alzheimer's disease psychosis. Our approach allows us to precisely target neural circuits implicated in these disorders, leading to more effective and safer therapies with fewer side effects. We are a rapidly growing company with a strong emphasis on scientific rigor and collaborative innovation. Our tech stack includes tools like Google Tag Manager for analytics, a robust mobile-first website design, and secure infrastructure incorporating HSTS and DNSSEC. We foster a dynamic and supportive environment where cutting-edge science meets practical application. Our team values collaboration, creativity, and a commitment to making a significant impact in the field of neuroscience. We're backed by leading investors such as 5AM Ventures, Cowen Healthcare Investments, and Novo Holdings, and have recently completed a Series C funding round. We are currently expanding our team and seeking talented individuals passionate about transforming the treatment of brain disorders. Our focus is on bringing groundbreaking treatments to patients, making a real difference in their lives, and contributing to the advancement of neuroscience. We offer competitive salaries and benefits, opportunities for professional development, and a collaborative work environment where individuals can thrive. We are committed to providing all qualified applicants with consideration for employment without regard to race, color, religion, sex, national origin, sexual orientation, gender identity, disability status, protected veteran status, or any other characteristic protected by law.

🏢 Dotmatics
👥 501-1000💰 Private about 7 years agoPharmaceuticalComputerBiotechnologyBiopharmaBioinformaticsCloud ComputingLife ScienceSaaSData IntegrationData Visualization
Website LinkedIn Email Facebook Twitter

Dotmatics is an R&D scientific software company that specializes in connecting science, data, and decision-making. Their enterprise R&D platform and applications are designed to drive efficiency and accelerate innovation.

🏢 Teva Pharmaceuticals
💰 $100,000,000 Post-IPO Equity about 1 year ago🫂 Last layoff over 2 years agoPharmaceuticalBiopharmaMedicalHealth Care
Website LinkedIn Email Facebook Twitter

Teva Pharmaceuticals is a pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients.

🏢 Ganymede
👥 1-10💰 $12,750,000 Series A over 2 years agoBiopharmaLife SciencePaaSEnterprise SoftwareSoftware💼 Private Company
Website LinkedIn Email

Ganymede is a low-code bio-aware PaaS for biotech software engineering, facilitating easy data integration and pipeline construction for software engineers in the biotech industry.

🏢 Foresite Labs
👥 11-50BiotechnologyBiopharmaMedicalHealth Care💼 Private Company
Website LinkedIn Email

Foresite Labs is a biotechnology company pioneering the use of data science to accelerate the discovery and development of new medicines. We incubate and build healthcare companies, connecting impactful changes in patient outcomes to the entire therapeutic development lifecycle. Our unique approach leverages advanced analytical techniques and a rigorous scientific process, resulting in a pipeline of innovative treatments. We're a fast-growing company with a collaborative and flexible work environment. Our engineering team utilizes a robust tech stack including Python, SQL, AWS cloud platforms, and various workflow systems (like Nextflow, WDL/CWL, and Airflow). We value reproducibility and build efficient, automated analytical pipelines. We foster a culture of collaboration among scientists and engineers, ensuring seamless integration of various data types and the development of user-friendly analytical tools and dashboards. Foresite Labs offers competitive salaries and excellent benefits, alongside the opportunity to contribute meaningfully to advancements in healthcare. We are an equal opportunity employer committed to diversity and inclusion, valuing the unique perspectives and experiences our team members bring. We are headquartered in San Francisco and Boston. With significant funding and a portfolio of promising ventures, Foresite Labs is poised for continued growth and success in transforming healthcare through data-driven innovation. Join us and be a part of shaping the future of medicine.

🏢 Dianthus Therapeutics
👥 11-50💰 $230,000,000 Post-IPO Equity about 1 year agoBiotechnologyBiopharmaHealth Care📈 Public Company
Website LinkedIn

Dianthus Therapeutics is a clinical-stage biotechnology company pioneering novel monoclonal antibody treatments for severe autoimmune and inflammatory diseases. Our lead product, DNTH103, targets a specific part of the immune system and is designed for self-administration in some patients. We're making a significant impact in the biopharma industry by focusing on improved selectivity and potency, leading to more effective and targeted therapies. Our tech stack includes a robust mix of modern technologies such as Cloudflare JS, Google Cloud, and Cloudinary, reflecting our commitment to efficient and scalable development. We foster a collaborative engineering culture that embraces innovative approaches and prioritizes data-driven decision-making. We value scientific integrity, continuous learning, and a dedication to improving patient lives. We offer remote work opportunities and support a diverse and inclusive environment. Dianthus is a publicly traded company (NASDAQ: DNTH) with a strong funding history and a growing team of experienced professionals in biotech and pharma. We are actively expanding our team to support the advancement of DNTH103 through clinical trials and eventual commercialization. Join us in our mission to bring life-changing treatments to patients battling serious autoimmune diseases. We offer a supportive and flexible work environment which embraces remote work. Join our growing team and make a significant impact on the lives of patients suffering from autoimmune diseases. We are committed to providing transformative medicines for people living with severe autoimmune and inflammatory diseases.

Shown 10 out of 13